Oral pazopanib improves sight in macular degeneration cases

October 11, 2013
Oral pazopanib improves sight in macular degeneration cases
Oral pazopanib is well tolerated and improves mean best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness at day 29 in a small, per-protocol, non-rescued population of patients with age-related macular degeneration, according to a study published online Oct. 10 in JAMA Ophthalmology.

(HealthDay)—Oral pazopanib is well tolerated and improves mean best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness at day 29 in a small, per-protocol, non-rescued population of patients with age-related macular degeneration (AMD), according to a study published online Oct. 10 in JAMA Ophthalmology.

Megan M. McLaughlin, from GlaxoSmithKline in King of Prussia, Pa., and colleagues conducted a 14-day, placebo-controlled, dose-rising study in 72 healthy participants (oral pazopanib tablets, 5 to 30 mg daily) and a 28-day phase 2a open-label study in 15 patients with subfoveal choroidal neovascularization secondary to AMD (15 mg daily).

The researchers found that oral pazopanib was well tolerated by all. Rescue therapy before day 29 was received by six of the 15 patients, all of whom had the CFH Y402H CC "high-risk" genotype for AMD. The other nine patients completed the study without rescue with improvements from baseline in best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness. The association between the CFH Y402H T allele ("low risk" for AMD) trended toward improvement.

"It is postulated that CFH Y402H genotype may help predict which respond to pazopanib," the authors write.

Several authors disclosed financial ties to GlaxoSmithKline, which manufactures pazopanib and funded the study.

Explore further: Pazopanib shows better quality-of-life in advanced kidney cancer

More information: Abstract
Full Text

Related Stories

Pazopanib shows better quality-of-life in advanced kidney cancer

August 21, 2013
Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer ...

Impaired autophagy associated with age-related macular degeneration

August 21, 2013
A new study published in the prestigious PLoS One journal changes our understanding of the pathogenesis of age-related macular degeneration (AMD). The researchers found that degenerative changes and loss of vision are caused ...

Genotyping IDs long-term risk of macular degeneration

November 13, 2012
(HealthDay)—Genotyping of two genetic risk alleles can be used to estimate the long-term risk of early and late age-related macular degeneration (AMD), but knowing the phenotype is important in assessing risk when early ...

GEN reports on ocular therapeutics targeting the retina

September 10, 2012
Therapies for retinal diseases are expected to overtake those for glaucoma by 2014, reports Genetic Engineering & Biotechnology News (GEN). Because current retinal disease treatments only improve vision for six to eight weeks, ...

Supplement aids age-related macular degeneration

March 26, 2013
(HealthDay)—A supplement containing a combination of lutein, zeaxanthin, and ω-3 long-chain polyunsaturated fatty acids (LC-PUFAs) significantly benefits patients with age-related macular degeneration (AMD), according ...

Imeglimin beneficial as add-on to metformin in T2DM

December 14, 2012
(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to ...

Recommended for you

Study advances gene therapy for glaucoma

January 16, 2018
While testing genes to treat glaucoma by reducing pressure inside the eye, University of Wisconsin-Madison scientists stumbled onto a problem: They had trouble getting efficient gene delivery to the cells that act like drains ...

New study offers added hope for patients awaiting corneal transplants

January 9, 2018
New national research led by Jonathan Lass of Case Western Reserve University School of Medicine has found that corneal donor tissue can be safely stored for 11 days before transplantation surgery to correct eye problems ...

Diabetic blindness caused and reversed "trapped" immune cells in rodent retinas

January 3, 2018
Johns Hopkins researchers have discovered a cell signaling pathway in mice that triggers vision loss in patients with diabetic retinopathy and retinal vein occlusion – diseases characterized by the closure of blood vessels ...

Ophthalmologists increasingly dissatisfied with electronic health records

December 29, 2017
Ophthalmologists' use of electronic health records (EHR) systems for storing and accessing patients' medical histories more than doubled between 2006 and 2016, while their perceptions of financial and clinical productivity ...

Higher omega-3 fatty acid intake tied to lower glaucoma risk

December 26, 2017
(HealthDay)—Increased daily intake of ω-3 fatty acids is associated with lower odds of glaucoma, but higher levels of total polyunsaturated fatty acid (PUFA) intake are associated with higher odds of developing glaucoma, ...

Protein analysis allows for treatment of eye-disease symptoms with existing drugs

December 21, 2017
Demonstrating the potential of precision health, a team led by a researcher at the Stanford University School of Medicine has matched existing drugs to errant proteins expressed by patients with a rare eye disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.